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Low-dose radiotherapy to the testis is effective in eradicating testicular intraepithelial neoplasia (TIN, carcinoma in situ of the testis) at
the risk of androgenic deficiency. The present trial was designed to define the lowest dose effective to control TIN assuming a dose–
response relation of radiation-induced endocrinological damage. Patients with TIN in a solitary testicle or with bilateral TIN were
treated with 18Gy (14 patients) and 16Gy (26 patients) (5 2Gy per week). Biopsies to ascertain clearance of TIN were performed
after 6 and 24 months. The median time of follow-up is 20.5 months. There were three adverse events. In one patient, relapse of TIN
along with microinvasive seminoma was observed 2 years after 16Gy irradiation. In two other patients, persistent spermatogonia
were observed with the 16 and 18Gy regimen after 6 and 24 months, respectively. All other post-treatment biopsies showed the
Sertoli cell-only pattern. These results confirm that TIN is a radiosensitive lesion efficiently controlled in most cases with doses below
20Gy. However, sporadic failures may occur. A dose of 16Gy is probably unsafe and should no longer be used. Future investigations
should not only focus on total dosage of irradiation but also on fractionation schedules.
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Testicular intraepithelial neoplasia (TIN; also called carcinoma in
situ of the testis) is the uniform precursor of testicular germ cell
tumours (Dieckmann and Skakkebaek, 1999). According to the
current theory of the histogenesis of testicular tumours, TIN
evolves from embryonic germ cells and thus it is present in the
testicle many years before the tumour becomes invasive.
Morphologically, TIN consists of large intratubular cells that
closely resemble embryonic gonocytes (Rorth et al, 2000).
Diagnosis is achieved by testicular biopsy and immunohistological
examination with staining for placental alkaline phosphatase
(PlAP). If TIN is left untreated after diagnosis, malignancy will
develop in 50% of cases after 5 years and in 70% after 7 years,
respectively. Probably, all cases of TIN will ultimately proceed to
invasive testicular cancer (Skakkebaek et al, 1987). TIN can be
effectively treated by low-dose radiotherapy. This treatment is
appealing because TIN and thus the risk of testis cancer is
eliminated without surgical castration. Moreover, the testosterone-
producing Leydig cells are largely preserved and, consequently,
hormone supplementation is usually not required in these
individuals. So far, experience with radiotherapy of TIN is limited.
According to early experience (von der Maase et al, 1986;
Giwercman et al, 1991; Dieckmann et al, 1993), a total dose of
18–20Gy is sufficient to clear the testis from TIN (Bamberg et al,
1997); however, it became obvious that this dosage also causes
damage to the Leydig cells in at least one quarter of the patients
(Dieckmann et al, 2001; Classen et al, 2001), rendering these
patients dependent on androgen substitution. Therefore, a clinical
trial was initiated to look for the most appropriate radiation dose
that is still sufficient to eradicate TIN effectively, and that
preserves Leydig cell function at the same time. Owing to
unexpected outcomes, we here report interim results of this trial
with respect to control of TIN by radiotherapy. The endocrino-
logical data are still premature and will be reported later.
Patients and methods
A two-stage phase II study design was used for the trial (Simon,
1989). A stepwise dose-reduction schedule was employed starting
at the 18Gy level with dose-reduction steps of 2Gy each. Dosage
decrease was scheduled until treatment failure at any dose level
was experienced or until the 12Gy level was reached. According to
the two-stage design of the trial, dose reduction on each dose level
was employed after a minimum of seven patients had completed
treatment on this level without adverse events, that is without
persistence of TIN or germ cells, respectively, as evidenced by
post-treatment biopsy (Simon, 1989). In the case of treatment
failure at a given dose level, it was intended to confirm the safety of
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lthe corresponding next higher dosage level (+2Gy) by a further
sample of 24 patients for a population of 31 patients on this dose
level (Simon, 1989).
Irradiation was applied according to international standards in
2Gy fractions with five applications per week. The target volume of
radiotherapy was prescribed to a mid-testicular reference point,
which was set to 100%. The minimum target volume dose allowed
was 85% and the maximum volume dose was limited to no more
than 107%. Radiotherapy was delivered by a single anterior
electron beam field on a linear accelerator with a median energy of
11MeV (range 4–18MeV).
Biopsies to ascertain clearance of TIN were performed after 6
months and again after 2 years. In all cases, the histological
diagnosis of TIN as well as the absence or persistence of TIN in
post-treatment biopsies was confirmed by a reference pathologist
(VL). Histological work-up involved conventional histology and
immunohistological examination as detailed previously (Loy et al,
1990). Treatment failure was defined as the persistence or relapse
of TIN as observed histologically by biopsy, and, alternatively, as
the occurrence of an invasive testicular tumour as observed
clinically. Endocrinological evaluations were done prior to radio-
therapy and repeatedly during follow-up. These data will be
reported in a separate communication.
After initiation of the trial on the 18Gy dose level, dose
reduction was terminated prematurely at the 16Gy level because
we became aware of a TIN relapse on the 14Gy level from a
concurrent Danish trial (Skakkebaek, personal communication,
1999). According to a protocol amendment, we then proceeded to
apply 16Gy in a patient sample large enough (calculated sample
size according to Simon (1989) n¼31) to prove the safety of this
dosage to eradicate TIN.
Patients with histologically proven TIN in a solitary testis or
with bilateral TIN and without concurrent chemotherapy were
eligible for the trial. Patients had to sign informed consent
according to the declaration of Helsinki. The study was approved
by an ethical committee. The study was initiated in August 1998
and the present report is based on the cumulative data available on
31 December 2001.
RESULTS
Forty-three patients were entered on to the trial from 29
participating institutions (appendix). Three patients were excluded
because reference histology disclosed invasive seminoma in one
patient and the absence of TIN in two others. Thus, 40 patients
were evaluable for the study. Five patients had undergone
chemotherapy prior to radiotherapy: two had single agent
carboplatin (two courses) and three had full chemotherapy courses
with cisplatinum, etoposide and bleomycin (PEB). In each of these
patients, the persistence of TIN after chemotherapy had been
confirmed by biopsy.
Thirty-five patients had TIN in a solitary testicle, all of whom
had undergone surgery for a germ cell cancer in their contralateral
testicle. The right testis was involved in 19 cases, the left in 12;
laterality was unspecified in four patients. Four patients had
bilateral TIN. Median age was 30 years (range 20–45 years).
Median time of follow-up was 20.5 months (range 0.5–40 months).
Fourteen patients received 18Gy, and 26 underwent the 16Gy
regimen.
Acute toxicity of radiotherapy was low. Six patients experienced
skin toxicity grade I (RTOG score), three of whom had received
the 16 and 18Gy regimen, respectively. There was no toxicity
4grade I.
A total of 44 post-treatment biopsies were analysed histologi-
cally. The first and second biopsies were taken with a median time
to follow-up of 6.2 months (range 2.6–9.0 months) and 25.4
months (range 18.9–28.2 months), respectively. Further statistical
details are given in Figure 1. Histologically, three adverse events
were encountered: one relapse of TIN, one patient with persistence
of germ cells, and one other with reoccurrence of germ cells.
Overall, no persistence of TIN was observed in any post-
treatment biopsy at the 6-month checkpoint. However, in one
patient who had undergone the 16Gy regimen, several vital
spermatogonia were observed histologically. A second biopsy
taken from this patient after 2 years was clear of TIN and germ
cells. Currently, this patient is well and without clinical signs of
malignancy.
At the 2-year checkpoint, 10 biopsies were clear of TIN and germ
cells. However, TIN was detected in one patient who had been
found free of TIN 6 months after completion of irradiation with
16Gy. This patient subsequently underwent orchiectomy. Histo-
logical evaluation confirmed the presence of TIN in numerous
seminiferous tubules and, importantly, it also disclosed the
presence of microinvasive seminoma (Figure 2). Germ cells were
absent in the orchiectomy specimen. In a second patient treated
with 18Gy, Sertoli cells only were found 6 months after completion
of therapy, but isolated germ cells were detected in the second
biopsy 2 years after radiotherapy. This patient is under continuous
observation without clinical signs of testicular malignancy.
DISCUSSION
The finding of a TIN relapse after 16Gy radiotherapy is clearly
nonanticipated. At the outset of the present study, the expectation
based on the cumulative international experience (Giwercman et al,
1991; Mumperow et al, 1992; Dieckmann et al, 1993; Classen et al,
1998; Kazem and Danella, 1999; Sedlmayer et al, 2001) had been
that 14Gy or possibly even 12Gy radiotherapy would still be
sufficient to eradicate TIN.
Failure of chemotherapy to eliminate TIN and likewise its
inefficacy of preventing contralateral germ cell tumours has been
observed in abundance (Hoff-Wanderas et al, 1997; Christensen
et al, 1998; Ostau et al, 2001). Accordingly, there were five patients
Patient accrural
Experimental treatment
6 months checkpoint
2 years checkpoint
Enrolled for the trial
n=43
Eligible
n=40
Excluded:  
• seminoma: n=1
• no TIN : n=2
18 Gy: n=14 16 Gy: n=26
Control biopsies: n=12 Control biopsies: n=20
Control biopsies: n=5 Control biopsies: n=7
Figure 1 Study population and follow-up biopsies after radiotherapy.
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lwith persistent TIN after chemotherapy in the present series.
Primary resistance of TIN cells to chemotherapy, and possibly,
protection from chemotherapy by the blood–testis barrier are the
probable biological reasons for the inefficacy of chemotherapy to
cure TIN.
The reasons for the relapse of TIN despite radiotherapy are
unclear. Technical failure is improbable since in the present case
the first post-treatment biopsy had demonstrated the absence of
TIN and germ cells.
A feasible explanation would be the hypothesis that some of the
TIN cells in the present patient were somehow radioresistant and
thus escaped eradication. Presumably, in the present patient a few
TIN cells had been present even at the 6-month checkpoint.
Obviously, because of their low number and focal arrangement,
they escaped detection by biopsy at that time. The surviving TIN
cells resumed replication in the later course and were then large
enough in number and topographic distribution to be detected by
the biopsy at 2 years.
Further, the observation of persisting vital spermatogonia after
16Gy and even after 18Gy is incompletely understood, too. Such a
finding has not been reported previously. Since spermatogonia and
TIN cells share a number of biological features, it must be
suspected that the persistence of germ cells after radiotherapy
might herald also the persistence of TIN cells.
A further note is that the median follow-up is still low (20.5
months) in the present series. As the relapse has been found in a
biopsy after 2 years and only 12 patients have passed this
checkpoint to date, it could be suspected that even more relapses
might be disclosed during longer follow-up. Thus, the adverse
events reported here, although constituting only early experience,
clearly indicate that the 16Gy regimen involves a significant
potential of treatment failure, and even the 18Gy dose level may
finally prove to be insufficient for safe eradication of TIN.
Recently, Petersen et al (2002) reported the recurrence of TIN
after 14Gy irradiation with a standard fractionation schedule. In
analogy to our patient, that relapse was observed 2 years after
completion of treatment. In contrast to our study, Petersen et al
did not encounter relapse of TIN at the 16Gy level. Furthermore,
they did not observe persisting germ cells after the 16 and 18Gy
irradiation schedule. Possibly, small patient samples in both of the
studies (the present one and the Petersen study) account for these
incongruent findings. Interestingly, endocrinological compromise
was present in many of the patients in the Petersen study with no
significant differences between the various dose levels. In all, that
report strongly accords with our observation that a dose reduction
below 18Gy involves a small but definite risk of treatment failure.
In addition, it appears equivocal so far that a dose reduction of
radiotherapy will ultimately translate into a substantial clinical
benefit for the patient, that is, improved preservation of androgen
synthesis.
Clearly, another important lesson to be learned from the present
trial is that biopsies to control radiotherapeutic success are
paramount. Moreover, late biopsies (e.g. after 2 years) are much
more appropriate than early biopsies (i.e. after 6 months).
Possibly, even very late biopsies after 3 or 4 years could be useful.
If one assumes a persistence of TIN subsequent to radiotherapy,
then this condition probably consists of a tiny focus, morpholo-
gically. A random biopsy taken 6 months thereafter probably has a
large potential to miss that lesion. However, as TIN will inevitably
resume replication, biopsies taken during later follow-up have a
much higher chance of detecting the condition.
The dose–response relation of TIN is unknown so far. Owing to
morphological similarity, it is assumed that TIN and spermatogo-
nia are at least partly comparable with respect to radiosensitivity.
Germ cells are highly vulnerable to radiotherapy. Even scatter
doses from radiotherapy to abdominal or pelvic target organs can
cause significant damage to the germinative epithelium (Classen
and Bamberg, 1999). Depletion of germ cells is usually achieved
after total doses exceed 12–14Gy depending on the fractionation
schedule (Shalet, 1993).
In contrast to other tissues, germ cells are particularly sensitive
to fractionated irradiation. This phenomenon is because of
different radiosensitivity of the various stages of germ cell
maturation. Type A spermatogonia, the presumed stem cells of
spermatogenesis, are rather radioresistant possibly due to their
long cell cycle. Type B spermatogonia have a much shorter cycle
time, which may be the reason for their increased radiosensitivity.
Based on the morphological and biological similarities of
spermatogonia and TIN cells, it could thus be speculated that
not only the total dose of radiation but also the fractionation
schedule is critical for cure of TIN by radiotherapy. Accordingly,
Sedlmayer et al (2001) reported the efficacy of a 13Gy total dose
applied in 10 fractions to eradicate TIN at least in a short time to
follow-up and in a small cohort of patients.
According to standard fractionation regimens, a dose–response
curve as shown in Figure 3 may be hypothesised for local
radiotherapy of the testis (Figure 3). Total doses of 16Gy or more
will cure TIN in the majority of cases, but some of the cases will
relapse or persist as demonstrated in the present study. Doses of
18–20 Gy will cure TiN in almost 100% of cases. However, sporadic
relapse may occur even after standard dose treatment (Do ¨tsch
et al, 2000; Dieckmann et al, 2002). If higher doses are applied, no
Seminoma
TIN
70µ
Figure 2 Seminoma and testicular intraepithelial neoplasia after 16Gy radiotherapy; PlAP, orig.  120.
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lnew growths have been observed (Read, 1987). With regard to the
dose–response curve (Figure 3), it may be speculated that the
curve could be shifted to the left by decreasing the daily dosage
below the classical 2Gy standard dose and by increasing the
number of fractions at the same time. Thus, higher cure rates
might be achieved with lower total doses. Furthermore, reduced
single doses of treatment might contribute to protect androgen-
producing Leydig cells from late sequelae of irradiation.
In conclusion, it becomes obvious that control of TIN by current
radiotherapeutic strategies is not possible in virtually 100% of
cases. High cure rates are achievable even with doses of
radiotherapy just below or around the 20Gy level, but sporadically,
relapses may occur. The optimal dose of radiotherapy is yet to be
found. Total doses of 16Gy with standard fractionation is
obviously not safe enough and should no longer be used.
Conceivably, a schedule with higher fractionation may offer
another convenient avenue to dose reduction and thus preserva-
tion of hormone-active Leydig cells.
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Figure 3 Dose–response curve hypothesised for radiotherapy of TIN.
Increasing the number of fractions may shift the response curve to the left.
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